SLC5A2 and type 2 diabetes mellitus: We believe that clinical trials are necessary to establish secondary prevention measures related to attenuating the cardiovascular complications of T1D, even considering the use of other drugs that have demonstrated cardiovascular benefits in patients with T2D, such as SGLT2 inhibitors or GLP-1 analogues.